%0 Journal Article
%T Bevacizumab in extensive-disease small cell lung cancer: the search continues
%A Apar Kishor Ganti
%A Avyakta Kallam
%J SCIE-indexed Journal
%D 2017
%R 10.21037/13483
%X The outcomes of extended stage small cell lung cancer (ED-SCLC) have remained unchanged over the past two decades, with a median survival of 10 months and a 2-year survival of 10%, despite addition of radiation therapy to certain subsets of patients (1). The combination chemotherapy with cisplatin and etoposide has remained unchanged since the late 1990¡¯s (2), despite testing multiple different agents, both cytotoxic and targeted agents
%U http://tcr.amegroups.com/article/view/13483/html